RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Total current liabilities

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$82.2B
P/E ratio
SummaryFinancials
Period EndTotal current liabilities (Million USD)YoY (%)
Dec 31, 20243,944+15.22%
Dec 31, 20233,423+8.98%
Dec 31, 20223,141-20.12%
Dec 31, 20213,933+45.79%
Dec 31, 20202,697+28.66%
Dec 31, 20192,097+45.31%
Dec 31, 20181,443+27.06%
Dec 31, 20171,135-8.54%
Dec 31, 20161,241+53.05%
Dec 31, 2015811+23.91%
Dec 31, 2014655+119.07%
Dec 31, 2013299+82.72%
Dec 31, 2012164+10.30%
Dec 31, 2011148+35.96%
Dec 31, 2010109

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)